• 89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

    来源: Nasdaq GlobeNewswire / 06 2月 2024 15:05:00   America/Chicago

    SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 1:20 PM EST and participate in one-on-one investor meetings.

    The webcast of the presentation will be accessible here and in the investor section of 89bio’s website.

    About 89bio
    89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.

    Investor Contact: 
    Annie Chang 
    89bio, Inc.
    investors@89bio.com

    PJ Kelleher
    LifeSci Advisors, LLC
    +1-617-430-7579
    pkelleher@lifesciadvisors.com

    Media Contact: 
    Sheryl Seapy
    Real Chemistry
    sseapy@realchemistry.com


    Primary Logo

分享